Originally developed to prevent osteoporosis, Lassaxifen is a selective estrogen receptor modulator. In other words, Lassaxifen has both estrogen and anti-estrogen effects in different tissues, which is mainly mediated by the estrogen receptors.
Previous observational studies have found that compared with other drugs, lasofoxifene can effectively prevent breast cancer, and reduce the incidence rate of ER-positive breast cancer by 80%, in addition to inhibiting bone loss.
In addition, Lassaxifen has good safety, can maintain bone mineral density, prevent vaginal dryness, and does not stimulate the uterus.
But at present, although scientists have found that it is helpful to prevent breast cancer, it is not clear whether it has an anti-tumor effect.
In this new study, researchers in Chicago carried out experiments on mice, all of which had ER-positive breast cancer, and all of them had ER mutations.
The researchers treated some mice with Lassaxifen and others with fulvestrant.
In addition, they also tested the two drugs in combination with parecoxib.
Paxil is a commonly used chemotherapeutic drug. It can prevent cancer cells from proliferating.
In the experiment, the researchers found that raloxifene alone was more effective than fulvestrant in preventing tumor growth and reducing cancer cell metastasis.
However, the combination of the two drugs can improve the efficacy of the two drugs.
This study shows that raloxifene is better than breast cancer in treating breast cancer, whether used alone or in combination with the use of the same method.
In addition to fewer side effects, tamoxifen has other significant advantages.
Unlike Galveston, which must be injected, Lassaxifen can be taken orally.
It also has a long half-life, which means that Lassaxifen will stay in the body longer.
Clinically, the desired effect is that whenever a new estrogen receptor is produced or the receptor is mutated, the drugs in the patient can inhibit it.
The advantage of Lassaxifen is that it works longer.
The University of Chicago is conducting a phase II clinical trial. They used raloxifene as a treatment for menopausal women who received second-line treatment. These women had ER-positive breast cancer, metastasis, and ER mutation.
Follow-up researchers will also continue to study the combination of Lassaxifen, a chemotherapeutic drug similar to penicillin.
At present, most ER-positive metastatic breast cancer women are treated with vitamins.
But according to the study, fulvestrant is not the best drug. For female patients, the applicability of Lassaxifen is better than that of fulvestrant.